Upstream Bio, Inc. (NASDAQ:UPB) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Daniella Beckman Other companies: Blueprint Medicines Corp (Director · Since at least Dec 8, 2021); Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Aug 10, 2021); Vor Biopharma Inc. (Chair of the Audit Committee · Since at least Feb 4, 2021); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Translate Bio Inc (Director · Jun 18, 2019 – Sep 14, 2021 · Past) | Member, Board of Directors · Since at least Oct 10, 2024 |
| Everett Rand Sutherland Other companies: Krystal Biotech, Inc. (Director · Since at least Jan 18, 2022); Allakos Inc (Director · Jul 31, 2023 – Aug 1, 2023 · Past); Translate Bio Inc (President · Mar 22, 2021 – Sep 14, 2021 · Past) | Chief Executive Officer, Director · Since at least Oct 10, 2024 |
| Michael Gray Other companies: POINT Biopharma Global Inc (Director · Jul 7, 2020 – Jul 7, 2020 · Past); Enliven Therapeutics, Inc. (CFO & COO · Mar 11, 2020 – Feb 22, 2023 · Past); X4 Pharmaceuticals, Inc. (President, CEO and CFO, Director · Nov 15, 2017 – Nov 27, 2018 · Past) | CFO and COO · Since at least Oct 10, 2024 |
| Harold Edward Fleming Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); CRISPR Therapeutics AG (Director · Since at least Jun 10, 2021) | Director · Since at least Oct 10, 2024 |
| Marcella Kuhlman Ruddy Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Tectonic Therapeutic, Inc. (Chief Medical Officer · Since at least Jun 20, 2024) | Chief Medical Officer, Tectonic Therapeutic · Since at least Oct 10, 2024 |
| Edd Fleming Other companies: Sionna Therapeutics, Inc. (Director · Since at least Nov 5, 2026) | Executive Vice President, Enavate Sciences · Since at least Nov 5, 2026 |
| Rand Sutherland Other companies: Krystal Biotech, Inc. (Board Member · Since at least Nov 5, 2026) | Chief Executive Officer · Since at least Aug 11, 2026 |
| Aaron Deykin | Chief Medical Officer & Head of R&D · Since at least Jun 16, 2026 |
| Adam Houghton | Chief Business Officer · Since at least Jun 16, 2026 |
| Allison Ambrose | General Counsel · Since at least Dec 16, 2024 |
| Amy Iannelli | Vice President, Finance · Since at least Nov 5, 2026 |
| Ashish Kalra | Vice President, Translational Research · Since at least Jun 5, 2025 |
| Christopher Silva | Vice President, Supply Chain · Since at least Nov 5, 2026 |
| Ken Adams | Senior Vice President, Clinical Operations & Medical Writing · Since at least Nov 4, 2026 |
| Liam Ratcliffe | Head of Biotechnology, Access Industries · Since at least Nov 5, 2026 |
| Marie Sanchirico | Vice President, Medical Affairs · Since at least Nov 5, 2026 |
| Meggan Buckwell | Director, Corporate Communications and Investor Relations · Since at least Mar 1, 2026 |
| Mersedeh Miraliakbari | Senior Vice President, Regulatory Affairs and Quality · Since at least Nov 5, 2026 |
| Mike Gray | Chief Financial Officer and Chief Operating Officer · Since at least Sep 17, 2026 |
| Parika Petaipimol | Vice President, Technical Operations · Since at least Nov 5, 2026 |
| Ron Renaud | Chair, Board of Directors · Since at least Nov 4, 2026 |
| Stacy Price | Chief Technology Officer · Since at least May 20, 2025 |
| Sumathi Sivapalasingam | Vice President & Head of Clinical Development · Since at least Nov 5, 2026 |